Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression

Leukemia and Lymphoma

Volumn 52, Issue 9, 2011, Pages 1787-1794

  Hao, Mu ^a   Zhang, Li ^b   An, Gang ^a   Meng, Hengxing ^c   Han, Youjin ^a   Xie, Zhenqing ^a   Xu, Yan ^a   Li, Changhong ^a   Yu, Zhen ^a   Chang, Hong ^d   Qiu, Lugui ^a,c  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b SICHUAN UNIVERSITY   (China)

^c Umbilical Cord Blood Bank of Tianjin ^*  (China)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

apoptosis; drug resistance; miRNA 15a; Multiple myeloma; stromal cells

Indexed keywords

BORTEZOMIB; INTERLEUKIN 6; MICRORNA; MICRORNA 15A; PROTEIN BCL 2; UNCLASSIFIED DRUG; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CELL ADHESION; CELL CONTACT; CELL CYCLE PROGRESSION; CELL SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; UPREGULATION;

APOPTOSIS; BONE MARROW CELLS; BORONIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; MICRORNAS; MULTIPLE MYELOMA; PYRAZINES; STROMAL CELLS; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052062422     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.576791     Document Type: Article

References (24)

1. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
2. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell 2004;6:439-444.
3. Gilbert LA Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell 2010;143:355-366.
4. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14:2519-2526.
5. Podar K, Chauha D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10-24.
6. Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009;114:3625-3628.
7. Nencioni A, Grü nebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007;21:30-36.
8. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-4916.
9. Anderson KC. Targeted therapy of multiple myeloma based upon tumor microenvironmental interactions. Exp Hematol 2007;35:155-162.
10. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-598.
11. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33:e179.
12. Chang H, Li D, Zhuang L, et al. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk Lymphoma 2004;45:965-969.
13. Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor in the pathophysiology of human multiple myeloma:therapeutic applications. Oncogene 2001; 20:4519-4527.
14. Gatt ME, Zhao JJ, Ebert MS, et al. MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood 2010 Oct 20. [Epub ahead of print]
15. Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669-6680.
16. Yanamandra N, Colaco NM, Parquet NA, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006;12:591-599.
17. San Miguel JF, Schlag R, Khuageva N, et al. MY-3002: a phase 3 study comparing bortezomib melphalan prednisone (VMP) with melphalan prednisone (MP) in newly diagnosed multiple myeloma. Blood 2007;110(Suppl. 1): Abstract 73.
18. Roorda BD, ter Elst A, Kamps WA, de Bont ES. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol 2009;69:187-198.
19. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005;105:1383-1395.
20. Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006;103:19478-19483.
21. Karaa ZS, Iacovoni JS, Bastide A, Lacazette E, Touriol C, Prats H. The VEGF IRESes are differentially susceptible to translation inhibition by miR-16. RNA 2009;15:249-254.
22. Hua Z, Lv Q, Ye W, et al. miRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006;1:e116.
23. Corthals SL, Jongen-Lavrencic M, de Knegt Y, et al. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res 2010;34:677-681.
24. Lee SO, Masyuk T, Splinter P, et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008;118:3714-3724.